System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Jair Bar is an expert in Oncology at Sheba Medical Center (Israel). As of October 2026, ScienceLeadR ranks Jair Bar in the top 1% of experts worldwide for Bronchial Neoplasms, Thoracic Neoplasms and Lung Neoplasms. Jair Bar has authored 245 publications, the most recent in 2026, and is an investigator in 21 clinical trials, 6 of them ongoing. SLR score: 1,296 (community average: 125). How the SLR is computed.

LeadR Profile

Jair Bar Sheba Medical Center Israel
1 296 ScienceLeadR Reputation 1296

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pulmonology - Biochemistry - Radiotherapy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2001 - 2026
Source: PubMed

Tel Aviv University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 245

Citations

Citations: 24 137 1st author: 46 Last author: 32 Unique author: 0

Main journals

J Clin Oncol 42
J Thorac Oncol 30
Ann Oncol 17
Cancer Res 12
Clin Lung Cancer 10

Best Journals

J Clin Oncol 27
Ann Oncol 12
N Engl J Med 7

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.
PMID 42532338 — research design, neoplasms, carcinoma, non-small-cell lung, uncertainty, therapeutics, rna		J Thorac Oncol20261
PD-L1 and PD-L2 regulate in cell-autonomous and N-glycosylation-dependent manners the pro-tumorigenic characteristics and functions of human cancer-associated fibroblasts.
PMID 42401791 — cytokines, cells, neoplasms, clinical medicine, cancer-associated fibroblasts, osteopontin, fibroblasts		Mol Med20260
Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.
PMID 42374088 — cells, lung, molecular biology, pharmaceutical preparations, neoplasms, lung neoplasms, small cell lung carcinoma		Nat Med Top journal20260
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.
PMID 42368479 — safety, neoplasms, carcinoma, non-small-cell lung, therapeutics		JTO Clin Res Rep20262
Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.
PMID 42296461 — pharmaceutical preparations, neoplasms, colorectal neoplasms		J Clin Oncol Top journal20260

Clinical Studies 21

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6

By phase:

Phase 3 10
N/A 5
Phase 2 3
Phase 1 2
Phase 1/Phase 2 1

By status:

Active not recruiting 8
Completed 6
Recruiting 4
Suspended 1
Terminated 1
Unknown 1

By type:

Interventional 16
Observational 5

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 1
multicentric5to9 1
multicentricup10 15

Main Topics

Ongoing Clinical Trials

6 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Real World Stage II III NSCLC Patients Receiving Neoadjuvant Chemo immunotherapy and no Surgical Resection
NCT07131163 — radiotherapy, cells, lung, neoplasms, disease progression, carcinoma, non-small-cell lung, drug therapy, positron emission tomography computed tomography, immunotherapy, lung neoplasms, small cell lung carcinoma, neoadjuvant therapy, therapeutics, chemotherapy, carcinoma		N/ARecruiting2024
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C mutant Non Small Cell Lung Cancer
NCT06890598 — cells, lung, safety, neoplasms, carcinoma, non-small-cell lung, immunotherapy, lung neoplasms, small cell lung carcinoma, carcinoma		Phase 3Recruiting2025
Neo Bio ADAURA a Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib
NCT06206850 — multiple chronic conditions, carcinoma, non-small-cell lung		Phase 2Recruiting2024
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV 706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors
NCT05599984 — cells, lung, safety, pharmaceutical preparations, neoplasms, drugs, investigational, drug therapy, central nervous system, drug therapy, combination, central nervous system neoplasms, drug-related side effects and adverse reactions, lung neoplasms, small cell lung carcinoma, therapeutics, nervous system, carboplatin, infusions, intravenous, nervous system neoplasms, carcinoma, neuroendocrine, pharmacokinetics, chemotherapy, carcinoma		Phase 1Active not recruiting2022
Met Non Small Cell Cancer Registry (MOMENT)
NCT05376891 — registries, cells, neoplasms, carcinoma, non-small-cell lung, therapeutics		N/ARecruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS